Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
An insurance denial for ketamine therapy, whether for Spravato (esketamine) nasal spray or compounded oral ketamine, is not a final answer. Federal law gives most patients the right to challenge a denial through an internal appeal with the insurer, an independent external review, and in some cases a state regulatory complaint or lawsuit. This guide explains how to appeal an insurance denial for ketamine step by step, from reading the denial notice correctly to requesting a peer-to-peer review and escalating if needed. If you have not yet gone through prior authorization, understanding how insurers currently evaluate ketamine coverage is worth doing before you appeal.
Appeals are common in ketamine treatment because coverage criteria are strict and documentation requirements are specific. Many denials are addressable with additional documentation or a focused clinical argument rather than a fundamental disagreement about whether the treatment is appropriate.
Quick Answer
Most health plans allow you to challenge a ketamine therapy denial through an internal appeal filed with the insurer, followed by a peer-to-peer review between your prescriber and the plan's medical director, and, if that fails, an independent external review. Federal laws including the Affordable Care Act (ACA), ERISA, and the Mental Health Parity and Addiction Equity Act (MHPAEA) set your rights and strict deadlines, typically 30 to 60 days for a standard internal appeal and 72 hours for an expedited one. Your best chance of success comes from directly addressing the insurer's stated denial reason with specific, organized clinical documentation.
Understanding why an initial request was denied helps you target the appeal. Common reasons insurers deny ketamine therapy claims include:
- Insufficient documentation of prior antidepressant treatment failures
- Disputes over what counts as an "adequate trial" of a prior medication
- Missing documentation of a concurrent antidepressant, which some plans require alongside Spravato
- Administrative errors, such as an incorrect billing code or missing paperwork
- Non-formulary status, which commonly affects compounded oral ketamine because compounded medications are not individually FDA-approved products and are not always listed on a plan's formulary
- An "experimental or investigational" determination
Most of these reasons are addressable with additional documentation or a focused clinical argument. A denial does not necessarily mean the insurer has concluded your treatment lacks merit. It often means the original submission did not include enough documentation to meet the plan's stated criteria.
Several federal laws protect a patient's right to appeal a health insurance denial:
- Affordable Care Act (ACA): a federal law requiring most non-grandfathered health plans to offer both an internal appeal and an external independent review, along with an expedited appeal process for urgent situations.
- ERISA: the Employee Retirement Income Security Act governs most employer-sponsored health plans and requires a formal appeal process, with legal remedies available if a claim is wrongfully denied.
- Mental Health Parity and Addiction Equity Act (MHPAEA): a federal law requiring that mental health and substance use treatment be reviewed under the same standards insurers apply to medical and surgical treatment. If a plan applies stricter review criteria to a ketamine or Spravato claim than it applies to a comparable medical claim, that difference can support a parity argument.
- State laws: many states add consumer protections beyond federal requirements, including shorter appeal timelines and guaranteed access to independent external review.
According to Healthcare.gov, the federal marketplace resource on coverage and appeal rights, patients on ACA-compliant plans have the right to both an internal appeal with their insurer and an external review conducted by an independent third party.
The Ketamine Insurance Appeal Process, Step by Step
Step 1: Understand the Denial
Request the written denial notice, which is required by law to state the specific reason for the denial and cite the plan provision or clinical criteria that was not met. Also request the clinical coverage policy the insurer used and the evidence basis, meaning the guidelines or research it relied on. Match each stated reason to documentation you can provide in response before you write anything.
Step 2: File the Internal Appeal
Every health plan must offer an internal appeal, your first formal challenge to the denial. A standard appeal typically gets a decision within 30 days if treatment has not yet started or 60 days if it has already begun. Build an appeal package that includes a clear appeal letter (patient and claim details, the stated denial reason, a summary of your clinical history, a table of prior antidepressant trials with drug, dose, duration, and outcome, and a direct rebuttal to each reason for denial) plus supporting records: a letter of medical necessity from the treating prescriber, clinical notes, validated depression rating scale scores such as PHQ-9 or MADRS, pharmacy records of prior antidepressant trials, and relevant published clinical evidence.
Step 3: Request a Peer-to-Peer Review
Ask your prescriber to request a peer-to-peer review at the same time you submit the written appeal. This is a direct phone call between your prescriber and the insurer's medical director, separate from but complementary to the written appeal. It lets your prescriber explain clinical nuance that is difficult to convey in paperwork and communicate urgency directly. It is widely considered one of the most effective steps in the process, though reversal rates vary by insurer and condition and are not consistently published. Give your prescriber all relevant documentation ahead of time and confirm the call happens within the appeal timeline.
Step 4: Request an External Independent Review
If the internal appeal is denied, the ACA gives most patients the right to an external independent review conducted by an independent review organization (IRO) under contract with your state rather than your insurer. You generally have 4 months from the internal appeal denial to request it, and the decision is typically binding on the insurer. Standard decisions are due within 45 days, and expedited decisions within 72 hours. Cost to the patient ranges from $0 to $25 depending on the state. Your denial notice should include instructions for requesting external review; if it does not, your state insurance commissioner's office can provide them. Employer-sponsored ERISA plans may follow a different external review process.
Step 5: Escalate If Needed
If the insurer has not followed required timelines, you believe the denial violates mental health parity, or you have exhausted internal and external appeals, you can file a complaint with your state insurance commissioner. This is a regulatory complaint rather than a formal appeal, and the commissioner's office can investigate and press the insurer to explain or reverse its decision. For ERISA plans where internal and external appeals have failed, the next step is a civil lawsuit under ERISA Section 502(a), which requires an attorney experienced in ERISA litigation. For state-regulated plans, state consumer protection and insurance laws may offer additional remedies.
Important
Appeal deadlines are strict and vary by plan and state. If a denial affects an active depressive episode or any situation where delay could jeopardize your health or ability to function, ask specifically for an expedited appeal, which insurers must decide within 72 hours under the ACA.
The Mental Health Parity and Addiction Equity Act (MHPAEA) can be a powerful argument in a ketamine denial appeal. If your plan covers other treatments that are similarly evidence-based but used off-label, which is common across psychiatry, then denying ketamine coverage based on off-label or non-FDA-approved status for a given use may raise a parity concern. The same applies if a plan uses stricter step therapy or prior authorization requirements for mental health treatment than it does for comparable medical treatment.
You can ask your insurer to provide a Non-Quantitative Treatment Limitation (NQTL) analysis, a comparison of how the plan applies coverage criteria to mental health benefits versus medical and surgical benefits. Discrepancies in that analysis can support a parity argument in your appeal. The Centers for Medicare and Medicaid Services and the Department of Labor oversee MHPAEA compliance and accept complaints about suspected violations.
Action Checklist for a Ketamine Appeal
- Start the appeal the same day you receive the denial; deadlines are strict.
- Address each denial reason specifically, with matching evidence, rather than writing a general rebuttal.
- Involve your prescriber early and give them everything they need to request a peer-to-peer review.
- Keep copies of every letter and note the date and name of every phone call.
- Consider a professional patient advocate if the appeal becomes complex.
- Expect that more than one round of appeal may be needed; multiple rounds are common.
Manage Cost While Your Appeal Is Pending
If your appeal is still in process, understanding how generic and brand pricing differ can help you plan for out-of-pocket costs in the meantime.
Learn More
Have questions about your specific ketamine insurance denial or your coverage options?
Frequently Asked Questions
A standard internal appeal decision typically arrives within 30 to 60 days depending on whether treatment has started. An expedited internal appeal is decided within 72 hours. External review decisions are typically due within 45 days, or 72 hours if expedited.
The core appeal rights are the same, but denial reasons often differ. Spravato denials commonly cite missing documentation of a concurrent antidepressant, while compounded oral ketamine denials more often cite non-formulary or experimental/investigational status because compounded products are not individually FDA-approved.
ERISA plans still must offer internal and external appeal processes. If both are exhausted, the next step is a civil lawsuit under ERISA Section 502(a), which generally requires an attorney experienced in ERISA litigation.
No. A peer-to-peer review is a phone conversation between your prescriber and the insurer's medical director that happens alongside your written appeal, not a substitute for filing one.
It is a comparison, which you can request from your insurer, of how the plan applies coverage rules such as prior authorization and step therapy to mental health benefits versus medical and surgical benefits. Differences revealed in this analysis can support a mental health parity argument in your appeal.
Share
Related Reading
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.